|
Volume 272, Number 41,
Issue of October 10, 1997
pp. 25743-25752
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.
An IgG Monoclonal Antibody against Dictyostelium
discoideum Glycoproteins Specifically Recognizes
Fuc 1,6GlcNAc in the Core of N-Linked Glycans
LOCALIZED EXPRESSION OF CORE-FUCOSYLATED GLYCOCONJUGATES IN
HUMAN TISSUES*
(Received for publication, November 15, 1996, and in revised form, July 15, 1997)
Geetha
Srikrishna
,
Nissi M.
Varki
§,
Peter C.
Newell
¶,
Ajit
Varki
§ and
Hudson H.
Freeze

From the Burnham Institute,
La Jolla, California 92037, the § Glycobiology Program,
Cancer Center, Department of Medicine, University of California,
San Diego, La Jolla, California 92093, and the ¶ Department of
Biochemistry, University of Oxford, South Parks Road,
Oxford OX1 3QU, United Kingdom
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
ABSTRACT
Core fucosylation of N-linked
oligosaccharides (GlcNAc 1,4(Fuc 1,6)GlcNAc 1-Asn) is a common
modification in animal glycans, but little is known about the
distribution of core-fucosylated glycoproteins in mammalian tissues.
Two monoclonal antibodies, CAB2 and CAB4, previously raised against
carbohydrate epitopes of Dictyostelium discoideum
glycoproteins (Crandall, I. E. and Newell, P. C. (1989)
Development 107, 87-94), specifically recognize fucose
residues in 1,6-linkage to the asparagine-bound GlcNAc of
N-linked oligosaccharides. These IgG3 antibodies do not
cross-react with glycoproteins containing -fucoses in other linkages
commonly seen in N- or O-linked sugar chains.
CAB4 recognizes core 1,6 fucose regardless of terminal sugars,
branching pattern, sialic acid linkage, or polylactosamine
substitution. This contrasts to lentil and pea lectins that recognize a
similar epitope in only a subset of these structures. Additional GlcNAc
residues found in the core of N-glycans from dominant
Chinese hamster ovary cell mutants LEC14 and LEC18 progressively
decrease binding. These antibodies show that many proteins in human
tissues are core-fucosylated, but their expression is localized to skin
keratinocytes, vascular and visceral smooth muscle cells, epithelia,
and some extracellular matrix-like material surrounding subpopulations
of lymphocytes. The availability of these antibodies now allows for an
extended investigation of core fucose epitope expression in development and malignancy and in genetically manipulated mice.
INTRODUCTION
L-Fucosyl residues in 1,6-linkage to the innermost
GlcNAc ("core fucose") are relatively common in mammalian
N-glycans. The enzyme
GDP-L-fucose:2-acetamido-2-deoxy- -D-glucoside
(Fuc Asn-linked GlcNAc) 6- -L-fucosyltransferase, which
catalyzes the transfer of L-fucose from GDP-fucose to the
Asn-linked GlcNAc, has been purified from human skin fibroblasts (1)
and substrate specificity studied in the porcine liver enzyme (2). The
enzyme has recently been cloned from porcine brain (3). A great deal of
attention has been drawn to the modifications near the nonreducing
terminus of oligosaccharides with the success of demonstrating
biological functions, e.g. sialyl Lewisx in
selectin binding (4), mannose 6-phosphate in lysosomal enzyme targeting
(5), sialic acids in protein recognition (6), polysialic acids in
neuronal development (7), and N-acetylgalactosamine 4-sulfate in pituitary hormonal regulation (8). In contrast, the
biological significance of core modifications in N-glycans has not been clearly elucidated.
The presence of a core fucose residue greatly enhances recognition of
N-linked sugar chains by lentil (Lens culinaris
agglutinin) and pea (Pisum sativum agglutinin) lectins (9).
Bourne et al. (10, 11) demonstrated that core fucose binds
within a small crevice of Lathyrus ochrus isolectin II, but
in its absence the Man 1,3Man arm of the oligosaccharide is in an
energetically less favorable conformation that prevents strong binding.
Thus fucose promotes the glycan to assume the critical conformation
required for lectin binding. More recently, Stubbs et al.
(12) showed that core fucose greatly influences the conformation and
flexibility of the Man 1,6Man antenna of the biantennary
oligosaccharide from porcine fibrinogen. These studies suggest that
core fucose residues could play important roles in defining
oligosaccharide conformations needed for specific carbohydrate-protein
interactions. For example, core fucosylation is required for
polysialylation of neural cell adhesion molecule by the specific
polysialic acid synthase (13) and is involved in regulation of
de-N-glycosylation by mammalian peptide
N-glycosidases (14).
The expression of many oligosaccharides is known to be highly regulated
in a tissue- and cell-specific manner, reflecting the differential
regulation of glycosyltransferases (15). Enhanced core fucosylation of
proteins such as 1-fetoprotein and
1-protease inhibitor in germ cell tumors, hepatocellular
carcinomas, and other neoplasms (16-19) suggests that this
modification may be restricted in normal human tissues. However, little
is known about the tissue distribution of core-fucosylated
glycoproteins in humans.
The literature is replete with histochemical studies that use lectins
to detect glycoconjugate expression in tissues (for recent reviews see
Refs. 20-22). Cytochemical staining obtained with L. culinaris agglutinin and P. sativum agglutinin is
considered as chiefly indicating the presence of core-fucosylated
glycans, although fucosylation only serves to enhance binding of these lectins to the trimannosyl core of complex oligosaccharides. Most of
the lectin histochemistry studies of adult and embryonic mammalian tissues include L. culinaris agglutinin and P. sativum agglutinin as part of lectin "mixtures" (23-28), but
in most cases the binding patterns have been similar to those obtained
with concanavalin A. Lectin binding studies also have other inherent
shortcomings, since many lectins with the same nominal specificity show
different staining intensities for the same cell or tissue structure
(29).
Monoclonal antibodies are more sensitive and specific than lectins, but
many of the established carbohydrate-specific monoclonal antibodies are
low affinity IgM types with significant cross-reactivities. IgG
monoclonal antibodies with increased specificity and sensitivity would
be more advantageous for in situ localization of
oligosaccharides in tissues and for detection by immunoassays. Also,
with the advent of new in vivo genetic approaches for
elucidating oligosaccharide function (30), transgenic expressions or
deletions of glycosyltransferases require high quality reagents to
assess tissue-specific distribution of oligosaccharides. IgG monoclonal
antibodies that recognize specific linkages should have a decided
advantage over lectins that are often defined by their monosaccharide
specificities.
During our study of a library of carbohydrate-specific monoclonal
antibodies made against Dictyostelium discoideum
glycoproteins, we found two IgG antibodies that specifically recognized
fucose residues linked 1,6 to the Asn-bound GlcNAc of
N-linked oligosaccharides. We used these antibodies to study
the expression of core-fucosylated glycoconjugates in human tissues,
and we find that they may have a much more restricted cell type
localization than previously believed.
EXPERIMENTAL PROCEDURES
Fucosylated BSA1
neoglycoproteins were generously provided by Dr. Ole Hindsgaul of the
University of Alberta, Edmonton, Alberta, Canada. They were prepared
and analyzed for sugar content as described previously (31, 32).
tert-Butoxycarbonyl-L-tyrosine oligosaccharides from porcine fibrinogen (pFg) and reducing oligosaccharides from recombinant erythropoietin (EPO) were generous gifts from Dr. Kevin
Rice, University of Michigan. They were characterized by proton NMR and
fast atom bombardment-mass spectrometry or a combination of
two-dimensional high pressure liquid chromatography mapping and
enzymatic digestions (33, 34). Horseradish peroxidase (HRP), honeybee
(Apis mellifera) venom phospholipase A2
(PLA2), pineapple stem bromelain, ovalbumin, pFg, porcine
thyroglobulin (pTg), human lactoferrin, human 1-acid
glycoprotein, polyclonal rabbit anti-HRP, HRP-agarose, PLA2
agarose, Aspergillus -xylosidase, biotinylated L. culinaris agglutinin, P. sativum agglutinin,
biotinylated anti-mouse IgG, avidin peroxidase, and immunoglobulin
isotyping kit were purchased from Sigma. Biotinylated Ulex
europeus agglutinin I lectin was from Vector Laboratories,
Burlingam, CA. Streptavidin-biotin kit was from Dako, Carpenteria, CA.
Goat anti-mouse IgG alkaline phosphatase conjugate was from Promega,
Madison WI. L. culinaris agglutinin-alkaline phosphatase
conjugate was obtained from E-Y Laboratories, San Mateo, CA. Chicken
liver -L-fucosidase was from Oxford Glycosystems, NY.
Lumiphos 530 was from Lumigen Inc. Southfield, MI. Proteinase K was
obtained from Boehringer Mannheim. Human tissues were obtained from the
Tissue Core Facility of the Cancer Center, University of California,
San Diego.
Production of Anti-Dictyostelium Monoclonal Antibodies
Production of monoclonal antibodies CAB2 and CAB4 against cell
surface proteins of D. discoideum was described earlier
(35). Immunoglobulin isotyping was done as per the manufacturer's
instructions.
Immunoassays
Spectrophotometric ELISA
Reference glycoproteins or
fucosylated BSA conjugates were immobilized on 96-well microtiter
plates, and the wells were blocked with 3% BSA in Tris-HCl saline
(TBS) overnight. They were washed and the antigens then allowed to
react with the CAB antibodies at concentrations of 4 µg/ml IgG, in
TBS containing 1% BSA and 0.1% Tween 20 for 1 h at room
temperature. The plates were then washed and incubated with alkaline
phosphatase-conjugated goat anti-mouse IgG, followed by development
with p-nitrophenyl phosphate substrate. They were read at
405 nm on an ELISA plate reader.
Chemiluminescence ELISA
pFg was coated onto the wells
of FluoroNunc Maxi-sorb plates and blocked with 1% gelatin
in phosphate-buffered saline (PBS). The wells were incubated with CAB4
at a concentration of 250 ng/ml in TBS containing 1% BSA and 0.2%
Tween 20 for 2 h at 37 °C, followed by incubation with alkaline
phosphatase-conjugated goat anti-mouse IgG. The plates were then
developed with Lumiphos-530 and were read on an Anthos-LUCY1
luminometer.
Preparation of Human Tissue Homogenates
Human tissues were homogenized with a BioHomogenizer in 50 mM Tris-HCl, pH 7.5, containing 0.1 M
2-mercaptoethanol and 1% SDS. Suspensions were centrifuged at 650 × g for 15 min, and the postnuclear supernatants were
harvested and centrifuged further for 30 min at 100,000 × g. After protein estimation, the supernatants were stored
frozen until analysis.
CHO Mutant Cell Lysates
Cell lysates from LEC10, LEC14, LEC18, and Lec13 CHO cell
mutants were kindly provided by Dr. Pamela Stanley, Albert Einstein College of Medicine, New York, NY. Cell extracts were made in 1.5%
Triton X-100, and postnuclear supernatants were analyzed by CAB4 in
immunoblots.
SDS-Polyacrylamide Gel Electrophoresis and Western Blot
Analysis
Proteins were separated by SDS-polyacrylamide gel
electrophoresis in 12.5% polyacrylamide gels under reducing conditions
and transferred to nitrocellulose membranes. The membranes were blocked overnight with 10% skimmed milk in TBS or 3% BSA in TBS, washed with
TBS containing 0.05% Tween 20, and incubated with either of the CAB
antibodies at concentrations of 4 µg/ml IgG for reference proteins, 1 µg/ml for human tissue extracts, and 400 ng/ml for CHO cell lysates
or with 2.5 µg to 5 µg/ml L. culinaris
agglutinin-alkaline phosphatase conjugate for 1 h at room
temperature. For the immunoblots this was followed by reaction with
alkaline phosphatase-conjugated goat anti-mouse IgG. Bound proteins
were visualized by incubating with 5-bromo-4-chloro-3-indolyl
phosphate/nitro blue tetrazolium (BCIP/NBT) substrate.
Affinity Purification, Fractionation, and Characterization of
Rabbit Anti-HRP
Antibodies to HRP are predominantly directed against core
modifications on its N-glycans, specifically
Xyl 1,2Man -, and Fuc 1,3GlcNAc -Asn. Commercial rabbit
polyclonal anti-HRP (purified IgG fraction) was affinity purified on a
column of HRP-agarose and further fractionated into
anti-Fuc 1,3GlcNAc and anti-Xyl 1,2Man - components by a second
affinity purification on a PLA2 column as described (36). The bound anti-fucose component reacted with all plant glycoproteins carrying Fuc 1,3GlcNAc in the core, and with PLA2 which
also carries the same modification, but it did not recognize
Fuc 1,6GlcNAc in the core of mammalian N-glycans. The
anti-xylose component that was isolated from the run-through fraction
of the PLA2 column was repurified on the same column and
was found to be completely free of the anti-fucose reactivity assayed
with PLA2. Details of the purification and characterization
of these antibodies will be described elsewhere.
Enzyme Digestions
-L-Fucosidase
One µg of honey bee venom
PLA2 or pFg were each incubated with 4 milliunits of
chicken liver -L-fucosidase at 37 °C for 20 h,
in a total volume of 50 µl in 100 mM citrate/phosphate
buffer, pH 6.0. A control tube containing each protein was incubated
without added enzyme. (The digestion was done with and without prior
denaturation of the proteins using 0.1% SDS, 100 °C for 2 min, and
the results were essentially the same for both treatments.) After heat
inactivation of the enzyme (100 °C, 5 min), the control and digested
proteins were tested for binding to CAB4 antibody using ELISAs. In
addition, control and digested PLA2 were also tested
against the anti-Fuc 1,3GlcNAc component of anti-HRP to determine the
specificity of the enzyme.
-Xylosidase
One µg of HRP was incubated with 50 milliunits of Aspergillus -xylosidase at 37 °C for
16 h, in 50 µl of 100 mM phosphate buffer, pH 6.0, containing 100 µM dithiothreitol. A control was incubated
without added enzyme. After heat inactivation of the enzyme, the
control and digested proteins were tested for binding to CAB4 using an
ELISA. Efficiency of digestion was monitored by checking loss of
reactivity of the digested protein with the purified
anti-Xyl 1,2Man - fraction of anti-HRP.
Isolation of Glycopeptides
Core 1,3-fucosylated
glycopeptides, core 1,6-fucosylated glycopeptides, and
non-fucosylated glycopeptides from HRP, pTg/pFg, and ovalbumin
respectively, were prepared from 50 mg of each protein by digesting
with 2.5-5 mg of proteinase K in 0.2 M Tris-HCl buffer, pH
7.5, for 24 h. The reaction mixture was boiled for 10 min and centrifuged. The glycopeptides were lyophilized and purified on a
Bio-Gel P2 column equilibrated with 0.1 M ammonium formate, pH 6.0. Fractions were assayed for neutral sugar, and void fractions were pooled and repeatedly lyophilized from water to remove ammonium formate. The glycopeptides were then reconstituted in water. Neutral sugar was measured by phenol sulfuric acid method, and total sugar concentration was calculated from the established structure of N-linked oligosaccharides from each protein.
Immunostaining of Tissues
Cryostat sections of human tissues (5-micron thickness) were cut
and air-dried. Sections were fixed in 10% buffered formalin for 20 min
followed by removal of the endogenous peroxidase with 0.03% hydrogen
peroxide if necessary, and by blocking of nonspecific binding sites
with 10% normal goat serum in PBS containing 1% BSA. Five-micron
paraffin sections were deparaffinized and rehydrated before proceeding
with the immunostaining. After washing, the antibodies were overlayered
onto serial tissue sections at predetermined dilutions (usually between
1 and 10 µg/ml), and the slides were incubated in a humid atmosphere
for 30 min at room temperature or overnight at 4 °C. The labeled
streptavidin biotin kit from Dako was used as per the manufacturer's
instructions or with PBS or TBS washes between every step, and
biotinylated anti-mouse IgG was then applied for 10 min followed by
either alkaline phosphatase or peroxidase-linked streptavidin for 10 min. After another wash, the appropriate substrate was added, and the
slides were incubated in the dark for 20 min. After a wash in buffer,
they were counterstained with hematoxylin, mounted, and viewed using an
Olympus BH2 microscope. Lectin staining was carried out using
biotinylated U. europeus agglutinin I, L. culinaris agglutinin, or P. sativum agglutinin. Incubation with the lectins was carried out in TBS containing 1% BSA
and 1 mM CaCl2, MgCl2, and
MnCl2, followed by alkaline phosphatase-conjugated
streptavidin and Fast Red as the developer.
RESULTS
Characterization of the Epitope Recognized by CAB2 and CAB4 as Core
Fuc 1,6GlcNAc
CAB2 and CAB4 are members of a group of IgG
monoclonal antibodies generated against cell surface glycoproteins of
the slime mold D. discoideum (35). Reactivity of these
antibodies to Dictyostelium cells or cell ghosts was lost or
reduced by periodate treatment or digestion with endoglycosidase F,
indicating that they were directed against N-linked
oligosaccharide epitopes (35). In the present study, they were found to
be of the IgG3 subclass. When tested in ELISAs against a panel of
glycoproteins with established glycan structures (Table
I), both the antibodies reacted with the
following: 1) PLA2 which has an oligomannose structure core substituted by fucose residues linked either 1,3 or 1,6 (or is
occasionally difucosylated) (37); 2) pFg which has complex biantennary
oligosaccharides, core-substituted with fucose linked 1,6 to GlcNAc
(33); and 3) human lactoferrin which has complex biantennary
oligosaccharides core-substituted with fucose linked 1,6 to GlcNAc,
and additional fucose residues linked 1,3 to GlcNAc on the antennae
(38). The antibodies did not bind to core 1,3-fucosylated plant
proteins such as HRP (39) or pineapple stem bromelain (40). The absence
of binding to the plant glycoproteins did not result from interference
by a 1,2 xylose residue in the core region of these sugar chains,
since -xylosidase digestion of HRP did not increase CAB4 reactivity
(Fig. 1). The effectiveness of this
digestion is evident from >75% reduction in binding of an affinity
purified antibody (see "Experimental Procedures") against 1,2
xylose (data not shown). CAB4 does not bind to non-core-fucosylated proteins such as 1) bovine fetuin, which has triantennary
oligosaccharides, (41); or 2) ovalbumin, which has hybrid
oligosaccharides, with an intersecting GlcNAc residue (42); or 3) human
1-acid glycoprotein, which has complex bi-, tri-, and
tetraantennary oligosaccharides, with some fucose residues linked
1,3 to an outer GlcNAc but lacks core fucose substitutions (43).
These results indicated that the CAB2 and CAB4 antibodies are probably
recognizing core Fuc 1,6GlcNAc on N-linked glycans.
Table I.
Reactivity of CAB antibodies with some reference glycoproteins
Reactivities of all proteins except bovine fetuin are shown in Fig. 1
and/or Fig. 2. References for structural elucidation of each of these
glycans are given in parentheses.
|
| Glycoprotein |
N-Glycan structure
|
|
| Reactive |
| Honey bee venom phospholipase
A2 |
Oligomannose glycan, with core
Fuc 1,3GlcNAc /core Fuc 1,6GlcNAc /difucosylation at the core
(37) |
| Porcine fibrinogen |
Complex biantennary glycan, with core
Fuc 1,6GlcNAc (33) |
| Human lactoferrin |
Complex biantennary
glycan, with core Fuc 1,6GlcNAc and outer Fuc 1,3GlcNAc (38)
|
|
| Non-reactive |
| Horseradish peroxidase |
Oligomannose
glycan, with core Fuc 1,3GlcNAc and Xyl 1,2Man (39)
|
| Pineapple stem bromelain |
Oligomannose glycan, with core
Fuc 1,3GlcNAc and Xyl 1,2Man (40) |
| Chicken egg
albumin |
Hybrid glycan, intersecting GlcNAc, no core substitution
(42) |
Human 1-acid glycoprotein |
Complex bi-, tri-,
and tetraantennary glycans, with outer Fuc 1,3GlcNAc and no core
substitutions (43) |
| Bovine fetuin |
Complex triantennary glycan,
with no core substitutions (41) |
|
Fig. 1.
Characterization of the epitope recognized by
CAB antibodies as core Fuc 1,6GlcNAc. HRP, dexylosylated HRP,
pFg, and bee venom PLA2 were coated onto microtiter plates
at concentrations ranging from 1 to 250 ng. Wells were incubated with
CAB4 (4 µg/ml IgG) and then with goat anti-mouse IgG alkaline
phosphatase. Plates were developed with p-nitrophenyl
phosphate substrate and read at 405 nm. Similar results were obtained
with CAB2 antibody (not shown).
[View Larger Version of this Image (19K GIF file)]
Fig. 1 shows CAB4 antibody binding to increasing amounts of pFg,
PLA2, HRP, and -xylosidase-treated HRP measured by
ELISA. Linearity was evident up to 100 ng with PLA2 and
pFg, with a lower detection limit of 2-5 ng. No reactivity was seen
even with 250 ng of either native or dexylosylated HRP. Similar results
were seen with CAB2 (not shown).
The specificity of both these antibodies was also established by
Western blots (Fig. 2). Since the binding
pattern for both antibodies is identical, data are shown only for CAB4.
A non-relevant monoclonal antibody served as a negative control. The
antibodies recognized only core Fuc 1,6GlcNAc containing proteins in
the blots. Background binding seen with ovalbumin and bromelain was eliminated at higher antibody dilutions (<2 µg/ml). pFg, like other
fibrinogens, is composed of three different polypeptides, A (69 kDa), B (57 kDa), and (51 kDa) chains. The B and chains
carry core-fucosylated biantennary N-glycans (33) and are
recognized by the CAB antibodies, but the non-glycosylated A chain
is not. In addition, a higher molecular mass (79 kDa) band is also
intensely stained by the antibody. Since fibrinogens are notoriously
heterogeneous, this may represent catabolic intermediates of fibrinogen
which are often present in plasma or other contaminating binding
proteins from commercial pFg.
Fig. 2.
CAB antibodies recognize only core
Fuc 1,6GlcNAc containing proteins in Western blots. 1 µg each
of seven reference glycoproteins was separated on 12.5% polyacrylamide
gels and blotted onto nitrocellulose membranes. After blocking, the
membranes were probed with CAB4 (4 µg/ml IgG) followed by incubation
with alkaline phosphatase-conjugated goat anti-mouse IgG and developed
with BCIP/NBT. Lane 1, HRP; lane 2, bee venom
PLA2; lane 3, pineapple stem bromelain; lane 4,
ovalbumin; lane 5, pFg; lane 6, human lactoferrin; lane 7, human 1-acid
glycoprotein. CAB2 showed identical staining pattern, and staining with
an unrelated antibody was negative (not shown).
[View Larger Version of this Image (54K GIF file)]
Binding Is Reduced When Core Fuc 1,6GlcNAc-containing Proteins
Are Defucosylated
Digestion of PLA2 or pFg with
chicken liver -L-fucosidase, which cleaves fucose in
1 6, 2, 3, 4 linkages, reduces binding >80% (Fig.
3). pFg has only core Fuc 1,6GlcNAc,
but PLA2 also has core Fuc 1,3GlcNAc. The digestion did
not cleave core 1,3 fucose residues in PLA2 since there
was minimal loss of reactivity when probed with the affinity purified
anti-Fuc 1,3GlcNAc fraction of anti-HRP (Fig. 3,
inset).
Fig. 3.
Binding of CAB antibodies to pFg or
PLA2 is decreased when the proteins are defucosylated.
1 µg of PLA2 or pFg was digested with chicken liver
-L-fucosidase overnight as indicated under
"Experimental Procedures." A control tube for each protein without
added enzyme was also incubated simultaneously. 100 ng protein each of
control and digest were analyzed in an ELISA for binding to CAB4. The
inset shows minimal loss of reactivity of PLA2
with the anti-Fuc 1,3GlcNAc fraction of anti-HRP, after digestion with the same fucosidase.
[View Larger Version of this Image (30K GIF file)]
Binding of CAB4 to pFg Is Inhibited by pTg/pFg Glycopeptides and
Reducing Oligosaccharides from Erythropoietin but Not by HRP or
Ovalbumin Glycopeptides
Biantennary glycopeptides containing
core-substituted Fuc 1,6GlcNAc were generated from pTg (44) or pFg.
These glycopeptides, or ones from HRP (core Fuc 1,3GlcNAc) and
ovalbumin (lacking core Fuc 1,6GlcNAc), were then compared for their
ability to inhibit CAB4 binding to pFg in spectrophotometric or
chemiluminescent ELISA. The latter method was adopted when <1 nmol of
free inhibitory oligosaccharides was available. As shown in Fig.
4, A and B, each assay gave comparable results. In both assays, HRP and ovalbumin glycopeptides did not block antibody binding, but pTg/pFg glycopeptides progressively inhibited CAB4 binding to pFg, again showing the specificity for core Fuc 1,6GlcNAc. Biantennary core-fucosylated oligosaccharide from EPO (EPO1, Fig. 4B) and pFg
(not shown) were equally effective inhibitors, showing that
GlcNAc-asparagine linkage is probably not required for recognition.
Fig. 4.
Binding of CAB4 to pFg is inhibited by
pTg/pFg glycopeptides and biantennary EPO oligosaccharides but not HRP
or ovalbumin glycopeptides. 25 ng (A) or 10 ng
(B) of pFg was coated onto an ELISA microwell plate
(A) or FluoroNunc Maxi-sorb plate (B) and the
wells were incubated with CAB4 (4 µg/ml IgG (A) or 250 ng/ml IgG (B)) in the presence of varying concentrations of
ovalbumin, HRP, or pTg/pFg glycopeptides, or biantennary EPO
oligosaccharide. The plates were developed with alkaline
phosphatase-conjugated anti-mouse IgG, and p-nitrophenyl
substrate (A) or Lumiphos 530 (B). Binding in the
absence of inhibitor was considered 100%.
[View Larger Version of this Image (16K GIF file)]
The Antibodies Do Not Recognize Fucose Residues in Other Linkages
Such as Those Seen in Lewis Antigens
To confirm that the CAB
antibodies did not recognize fucose residues in 1 2, 3, or 4
linkages to GlcNAc or Gal, we tested a panel of fucosylated
oligosaccharide-BSA conjugates using the spectrophotometric immunoassay
described in Fig. 1. Since the number of oligosaccharides per mol of
BSA varied, all were normalized to the same molar content of glycan.
The results in Table II show comparison
of the binding of the various Fuc glycans to the reactivity of 1.5 and
25 pmol of pFg. The first quantity of protein is within the linear
range of the assay for pFg, and the second is >10-fold above the
linear range, but all the neoglycoproteins were read within the linear
range of the assay. The antibodies did not recognize fucose residues in
Lewisa, Lewisb, or Lewisy,
3 -sialyl Lewisa or 3 -sialyl Lewisx (<0.1%).
Lewisx, Fuc 1,3GlcNAc , Fuc 1,4GlcNAc , and
Fuc 1,2Gal 1,3GlcNAc were very weakly recognized (<1.0%). This
weak reactivity of the different Fuc glycans suggests that not only the
fucose residue but the surrounding glycan and the linkage are important
for recognition by the antibody.
Table II.
CAB antibodies do not recognize -fucose residues in other linkages
The reactivity of pFg is considered 100% for each concentration. 1.5 pmol is within the linear range for pFg and gave a net A405 of 0.322. 1.5 pmol of Fuc-glycans gave a net
A405 <0.011.
|
| BSA-conjugate |
Glycans/per BSA
molecule |
Structure |
% binding versus pFg
oligosaccharides
|
| 1.5 pmol |
25 pmola
|
|
| 1 |
17 |
Gal 1,3GlcNAc |
2.5 |
0.075
|
|
|
4 |
|
|
|
|
|
Fuc 1
|
|
|
(Lewisa)
|
| 2 |
18 |
Fuc 1,2Gal 1,3GlcNAc |
1.8 |
0.17
|
| 3 |
18 |
Fuc 1,2Gal 1,3GlcNAc |
2.2 |
0.05
|
|
|
4 |
|
|
|
|
|
Fuc 1
|
|
|
(Lewisb)
|
| 4 |
38 |
Fuc 1,4GlcNAc |
3.3 |
0.56
|
| 5 |
16 |
Gal 1,4GlcNAc |
1.5 |
0.3
|
|
|
3 |
|
|
|
|
|
Fuc 1
|
|
|
(Lewisx)
|
| 6 |
16 |
Fuc 1,2Gal 1,4GlcNAc |
1.5 |
0.05
|
|
|
3 |
|
|
|
|
|
Fuc 1
|
|
|
(Lewisy)
|
| 7 |
15 |
Fuc 1,3GlcNAc |
2.6 |
0.9
|
| 8 |
13 |
3 -SialylLewisa |
2.9 |
0.05
|
| 9 |
9 |
3 -SialylLewisx |
1.0 |
0.065 |
|
|
a
25 pmol is beyond the linear range for pFg, but
extrapolation yields a A405 of 5.35. At 25 pmol,
most Fuc-glycans gave a net A405 of <0.01. Their
reactivity relative to that of pFg has been calculated from the
extrapolated value for pFg.
|
|
CAB4 Recognizes Core Fuc 1,6GlcNAc Found on Many Known
Oligosaccharides
A chemiluminescence immunoassay described in
Fig. 4B was used to test inhibition of CAB4 binding to pFg
by a wide variety of structurally characterized core
Fuc 1,6GlcNAc-containing glycans. The results using two
concentrations of each are shown in Table III. There is little difference between
the inhibitions seen using tert-butoxycarbonyl-L-tyrosine-linked pFg
biantennary chains terminated either by Sia 2,6,
Gal 1,4,GlcNAc 1,2 or the typical trimannosyl core. Oligosaccharide
chains from recombinant EPO give similar inhibitions to those seen
using the biantennary chains from pFg. The EPO glycans include those
with 2,3 Sia (EPO1), polylactosamine repeats (EPO5), triantennary
chains with different branching patterns (EPO4), and tetraantennary
chains (EPO8). Inhibition of CAB4 binding by the tri- and
tetra-branched chains is significant since neither P. sativum agglutinin nor L. culinaris agglutinin lectins
recognize core fucose when it is presented on tetraantennary and
triantennary chains disubstituted on the 1,3 core mannose residue
(45). These results show that CAB4 is not only highly specific but that it also recognizes a broader range of oligosaccharides than the lectins
commonly used to detect core fucosylation.
Table III.
CAB4 recognizes core Fuc 1,6GlcNAc on many known oligosaccharides
pFg was immobilized onto microtiter plates, and
t-butoxycarbonyl (Tyr-Boc) pFg oligosaccharide conjugates or
EPO oligosaccharides were used as competitors in the binding of CAB4 to
pFg at 20 or 100 nM in chemiluminescent assays. Results are
expressed as mean % of control binding, defined as 100%, in the
absence of inhibitor. Each value is the mean of two experiments, using
quadruplicate determinations for each
concentration.
|
|
Inhibitor |
Concentration |
Mean residual
binding |
|
|
|
|
Modifications in the N-Glycan Core Decrease Binding of CAB4 to
Proteins in Immunoblots
The above results clearly show that the
outer structures of sugar chains do not influence the binding of CAB4
to Fuc 1,6GlcNAc, but it is possible that modifications in the core
region, such as GlcNAc addition to the "bisecting" location
(GlcNAc 1, 4Man -), or 1,2 linked to Man -, or possibly
(GlcNAc / 1, 6)GlcNAc 1,4GlcNAc-Asn might block or reduce
antibody binding. Each of these structures was recently reported to
occur in CHO mutant cell lines LEC10, LEC14, and LEC18, respectively,
due to the activation of quiescent GlcNAc-transferases (46-48). These
mutants were originally selected for their resistance to ricin (LEC10)
or pea lectin (LEC14 and LEC18). To determine if these modifications
affected CAB4 binding, immunoblots of total cell lysates from wild-type
CHO cells or from mutants LEC10, -14, and -18 were tested in
immunoblots (Fig. 5). Bisecting GlcNAc
(LEC10) did not significantly alter binding compared with the parental
strain, whereas GlcNAc 1,2Man - (LEC14) and substitution on the
distal GlcNAc (LEC18) showed a progressive decrease in reactivity.
However, detection of this difference required careful titration of the
antibody; a 2-fold increase in antibody concentration eliminated the
difference from the control (not shown). All of the bands were specific
as shown by the competition with 50 µM pFg glycopeptides.
As a positive control, lysates from Lec13 cells which cannot synthesize
GDP-Fuc from GDP-Man and have fewer fucosylated chains (49) showed
considerably reduced binding. Residual bands observed with Lec13 are
also seen when specific CAB4 binding in lysates of parental cells is
blocked by pFg (Fig. 5) or when Lec13 lysates are probed with L. culinaris agglutinin (not shown). This residual binding could be
due to the ability of Lec13 cells to scavenge fucose, which could
partially correct their phenotype (49). These results suggest that the
currently known N-glycan core modifications have modest
inhibitory effects on CAB4 binding.
Fig. 5.
Other core modifications have minimal effect
on the binding of CAB4 to proteins. 10 µg each of LEC10, LEC14,
LEC18, and Lec13 mutant CHO cell extracts, and the parent CHO cell
extract (WT) were separated by electrophoresis on 12.5%
SDS-polyacrylamide gels, blotted onto nitrocellulose membranes, and
blocked with 10% milk in TBS. The membranes were incubated with CAB4
(400 ng/ml IgG). They were then developed with alkaline
phosphatase-conjugated goat anti-mouse IgG and BCIP/NBT substrate. The
last lane on the right shows inhibition of the
reactivity of wild-type extract with 50 µM pFg.
[View Larger Version of this Image (69K GIF file)]
Detection of Core-fucosylated Proteins on Immunoblots: A Wide Range
of Proteins Carry the Modification
Western blots of proteins from
different human tissues showed that many proteins were core-fucosylated
(Fig. 6A) especially in the
brain, heart, colon, ovary, placenta, and skin. Staining was less
intense in the liver and kidney at the antibody dilutions (1 µg/ml)
used but was appreciable at higher concentrations. Specific proteins
were stained in the lung, tonsil, and spleen. Binding was abrogated
when the blots were probed with the antibody in presence of 200 µM pTg glycopeptides or 50 µM pFg showing
that binding was specific. Examples of these inhibitions are shown for
heart, spleen, and skin.
Fig. 6.
A, Western blots of human tissue
extracts probed with CAB4. 50 µg of protein extract from each tissue
was separated by electrophoresis on 12.5% SDS-polyacrylamide gels and
blotted onto nitrocellulose membranes. The membranes were incubated
with CAB4 (1 µg/ml IgG), followed by development as described in Fig.
5. The last three lanes on the right represent
incubations done in the presence of 200 µM pTg
glycopeptides. B, a comparison of L. culinaris
agglutinin lectin blots and immunoblots of four different tissues. 50 µg of protein was separated in two different lanes for each tissue extract on SDS-polyacrylamide gels and electroblotted as described above. Lanes for each tissue were cut and incubated either with CAB4 (1 µg/ml IgG) or with L. culinaris agglutinin-alkaline
phosphatase (5.0 µg/ml). The antibody blots were incubated with
alkaline phosphatase-conjugated goat anti-mouse IgG, and both blots
were developed with BCIP/NBT.
[View Larger Version of this Image (82K GIF file)]
Fig. 6B shows a comparison of L. culinaris
agglutinin and immunoblots for brain, heart, skin, and placenta. An
alignment of protein bands stained either by L. culinaris
agglutinin or CAB4 shows that, depending on the tissue, approximately
35-50% of the bands corresponded to one another, although intensities
varied; however, at a 20-fold lower molar concentration, the antibody produces considerably sharper bands and a lower background compared with the lectin.
Immunolocalization of Core-fucosylated Proteins in Normal Adult
Human Tissues: Proteins Modified by Core Fucosylation Are Selectively
Localized
We used CAB2 and CAB4 to localize the expression of
core-fucosylated proteins in adult human tissues. Frozen and paraffin sections of heart, lung, liver, colon, pancreas, spleen, thymus, tonsil, ovary, skin, placenta, brain, and adrenal were examined. Although this modification is widespread, we obtained distinct and
localized staining patterns with the antibodies. Since binding patterns
were essentially the same for both the frozen and paraffin sections,
only examples of frozen sections are presented in Fig. 7.
Fig. 7.
Immunolocalization of core-fucosylated
glycoconjugates in human tissues. Frozen sections of human tissues
were stained with CAB2 or CAB4 (1-10 µg/ml IgG) as indicated under
"Experimental Procedures." In all tissues staining patterns were
almost identical for each of the antibodies, and hence the pattern with
either of the antibodies is presented for each tissue.
Arrows indicate areas stained. Magnifications and the
primary antibody used in each case are given in parentheses.
a, skin (20 ×, CAB4); b, heart (20 ×, CAB2);
c, lung (20 ×, CAB4); d, liver (10 ×, CAB2);
e, colon (20 ×, CAB4); f, ovary (10 ×, CAB4);
g, tonsil (20 ×, CAB2); h, spleen (20 ×,
CAB4).
[View Larger Version of this Image (157K GIF file)]
In the skin, the antibodies stained the cytoplasm of keratinocytes and
were especially prominent in the granular layer of the epidermis (Fig.
7a). Cells in the underlying dermis were not stained. The
antibodies selectively stained smooth muscle cells in five different
tissues. In the heart, smooth muscle of the coronary arterioles was
stained (Fig. 7b). In the lungs, only smooth muscle cells
surrounding the pulmonary arteriole were stained but not the smooth
muscle cells in the wall of terminal or respiratory bronchiole (Fig.
7c). The bronchiolar epithelium and the endothelium of the
blood vessels were also not stained. In the liver, the antibodies
stained the smooth muscle cells lining the hepatic arteriole in the
portal triad (Fig. 7d), but the endothelia of vessels,
epithelium of bile duct, parenchymal, and Kupffer cells were negative.
In the colon, smooth muscle cells of the muscularis mucosa were
selectively stained (Fig. 7e), whereas the mucosal epithelium and the smooth muscle of the muscularis externa were negative. In the ovary, the antibodies stained the smooth muscle cells
of the arteriolar walls, but the germinal epithelium, follicles, and
corpus luteum were not stained (Fig. 7f).
In the palatine tonsil the squamous epithelium lining was positive, as
was some extracellular matrix-like material (Fig. 7g) surrounding a subpopulation of lymphocytes. This was also seen in the
spleen and thymus (Fig. 7h). In the brain, the white matter of the cerebellum was stained (not shown).
The specificity of CAB4 binding in tissue sections was confirmed by
inhibition with pFg glycopeptides at 50 µM or less (not shown).
In contrast to the staining with the antibodies, biotinylated L. culinaris agglutinin or P. sativum agglutinin did not
stain specific recognizable structures above background in both
cryostat and paraffin-embedded sections (not shown). As a positive
control, biotinylated U. europeus agglutinin I, which is
specific for outer branch fucose in 1,2 linkage to Gal 1,4GlcNAc
(50), distinctly stained vascular endothelial cells in a variety of
tissues (not shown), in agreement with prior studies (51).
DISCUSSION
D. discoideum is a simple eukaryotic amoeba that can be
induced to develop into a multicellular organism in response to lack of
nutrients. Many of the glycans expressed during development in
Dictyostelium are highly immunogenic (52), although this organism does not synthesize complex-type oligosaccharides found in
mammalian cells (53). In Dictyostelium,
-L-fucose residues are presumed to be present both in
the peripheral and in the core regions of neutral oligosaccharides.
Those in the core are probably bound to the proximal GlcNAc on
N-linked oligosaccharides since they are resistant to
endoglycosidase H digestion (54, 55). Using the anti-Fuc 1,3GlcNAc
fraction of rabbit anti-HRP and the CAB4 antibody which recognizes core
Fuc 1,6GlcNAc, we have now obtained more direct evidence for the
occurrence and developmental regulation of both types of core
fucosylation in the glycoproteins of D. discoideum.2
In the synthesis of mammalian N-linked oligosaccharides,
addition of fucose is believed to be a terminal event occurring
exclusively on complex or hybrid structures (56). Identification of
core fucose residues in the high mannose type glycoproteins of D. discoideum appears to be inconsistent with existing in
vitro substrate specificity studies on mammalian core
1,6-fucosyltransferases which do not use oligomannose
N-glycans as acceptors (1, 2). Although this could be
explained as specificity difference, there is growing evidence that
fucosylated oligomannose structures do occur in mammalian cells. Lin
et al. (57) identified fucose residues in 1,6 linkage to
core GlcNAc in the N-glycans of GlcNAc-transferase 1-deficient Lec-1 CHO cells, which cannot synthesize complex or hybrid
N-glycans. More recently, Endo et al. (58)
documented the presence of novel fucosylated high mannose type sugar
chains in the oligosaccharides of the rat hepatoma alkaline
phosphatase. It is possible that the substrate specificities of the
fucosyltransferase in the in vitro studies do not adequately
reflect those in vivo.
CAB2 and CAB4 were previously found to recognize N-linked
glycans on Dictyostelium glycoproteins (35). In the present
work, immunoassays, immunoblots, enzyme digestion, and inhibition
studies all showed that these antibodies specifically recognize fucose residues in 1,6 linkage to the most proximal GlcNAc of
N-linked oligosaccharides (Figs. 1, 2, 3, 4). They did not
cross-react with proteins or neoglycoproteins that contained Fuc in
other linkages or in other positions commonly seen in N- or
O-linked glycans (Tables I and II). Binding to
core-fucosylated proteins was not inhibited by L-fucose
itself (data not shown). This is not uncommon; for example, the binding
of anti-HRP, which is directed against core 1,3 fucose and bisecting
1,2 xylose, is not inhibited by the haptenic sugars (59).
The binding of both L. culinaris agglutinin and P. sativum agglutinin to the trimannosyl core of N-linked
sugar chains is enhanced by the presence of core Fuc 1,6GlcNAc when
it is presented in the context of biantennary chains. These lectins
only recognize core-fucosylated triantennary complex chains when the
branching occurs on the 1,6 core mannose residue but not when it
occurs on the 1,3 core mannose residue (45). By contrast CAB
antibodies recognize core Fuc 1,6GlcNAc in all structures tested
including those not recognized by L. culinaris agglutinin
and P. sativum agglutinin (Table III). The smallest
structure tested
(Man3GlcNAc(Fuc 1,6)GlcNAc-Tyr-t-butoxycarbonyl) appears to block binding of CAB4 to pFg just as well as the largest tetraantennary structure (EPO8), suggesting that other sugars beyond
the core do not influence antibody binding. Using free oligosaccharides
and substituting the Asn with Tyr-t-butoxycarbonyl also
shows that the amino acid is not required for binding. The difference
between the binding specificities of L. culinaris agglutinin and P. sativum agglutinin and that of CAB antibodies could
be due to the fact that, although the lectins essentially bind to the
trimannosyl core of N-glycans, the antibodies may be
directed more against the core fucose residue itself.
The identification of gain-of-function mutants of CHO cells provided an
opportunity to explore novel modifications in the core that could
potentially interfere with recognition of the core Fuc 1,6 GlcNAc.
Addition of a 1,4GlcNAc to the -mannose residue in the core does
not change antibody binding (Fig. 5). However, addition of 1,2GlcNAc
to the -mannose or / -GlcNAc residue to the distal GlcNAc in
the core as seen in LEC14 and LEC18, respectively, appears to decrease
antibody binding in immunoblots. Addition of a GlcNAc residue to the
distal GlcNAc does not block the addition of Fuc1,6 to the proximal
GlcNAc (48), so decreased binding probably reflects a lower affinity of
the antibody. Increasing antibody concentration 2-fold leads to the
appearance of bands of normal intensity. As expected, both CAB4 and
L. culinaris agglutinin binding are also reduced, but not
eliminated, in lysates of Lec13 that cannot synthesize GDP-fucose from
GDP-mannose. The modest inhibitory effect of core GlcNAc substitutions
argues that the chitobiose core may not be required for, but may
influence, antibody binding. Also, this differential binding of the
antibody to N-glycans with modified core renders it useful
in identifying glycoproteins with these modifications.
Blots of tissue extracts probed with these antibodies showed that the
modification is widespread (Fig. 6a), but it has a
restricted and specific cell-type distribution (Fig. 7). Both cryostat
and paraffin-embedded sections show similar results in all tissues. Keratinocytes above the basal layer of the skin and particularly those
in the granular layer of the epidermis are selectively stained (Fig.
7a). Proliferation of keratinocytes occurs in the basal layer, and the cells differentiate as they move through the spinous and
granular layers to the tissue surface. Our findings suggest that core
Fuc 1,6GlcNAc may be a marker for terminal differentiation in the
epidermis. There are discrepancies in previous studies using L. culinaris agglutinin and P. sativum agglutinin to study differentiation of human skin. One study found that L. culinaris agglutinin stained the cytoplasm and periphery of
epidermal cells and also the dermis (23), and another study found that
P. sativum agglutinin stained the spinous and granular cell
membranes in human epidermis but not in the mouse epidermis (24).
Interestingly in the latter study, appreciable
-L-fucosidase activity, among other glycosidases, was
identified in the cells of the granular layer. Although cultured human
skin fibroblasts are rich sources of the core 1,6-fucosyltransferase
enzyme (1), we did not see any staining of fibroblasts (not shown).
This may be due to rapid secretion of the newly synthesized
glycoproteins.
A striking finding was the well defined staining of arteriolar smooth
muscle cells in the heart, lung, liver, and ovary and the smooth
muscles of the muscularis mucosa in the colon (Fig. 7,
b-f). Smooth muscle cells present in the tunica media of
vasculature are the major sources of elastin, collagen, and
proteoglycans in the extracellular matrix. These cells also have
multiple glycoprotein receptors for sympathetic and
parasympathetic neurotransmitters. For example, mammalian -
and -adrenergic receptors have complex N-linked glycans
(60, 61), and the muscarinic acetylcholine receptors can be
precipitated by L. culinaris agglutinin (62). The cerebellum
has a well defined cellular organization, and CAB4 binds to the white
matter in both frozen and paraffin-embedded sections (not shown).
N-Glycosylation is essential for oligodendroglial differentiation (63, 64). Cell surface neuronal and glial glycoproteins
isolated from human fetal brains bind to P. sativum agglutinin (28). Neural cell adhesion molecule in neuronal and glial
cells and in peripheral tissues including skeletal, cardiac, and smooth
muscle cells contain core Fuc 1,6GlcNAc (65).
In comparison to CAB antibodies, biotinylated L. culinaris
agglutinin and P. sativum agglutinin do not stain specific
structures in either the cryostat or the paraffin-embedded sections and
often produce heavy background staining. Under the same conditions, U. europeus agglutinin I intensely stains vascular
endothelial cells of many tissue sections, showing that these results
are not due to tissue processing methods or sample variations. CAB4 at
20-fold lower molar concentrations consistently shows better reactivities than L. culinaris agglutinin in
immunoblots.
By all criteria we have tested, CAB4 appears to recognize core
Fuc 1,6GlcNAc in most of the known N-linked
oligosaccharides. Of course we cannot be certain that all possible core
fucosylated N-linked oligosaccharides will react with the
antibody, but its binding specificity is as well characterized as that
of any carbohydrate-specific IgG antibody available. This, together
with the highly specific tissue localization of core fucosylation,
renders a linkage-specific tool to study tissue distribution of
oligosaccharides in transgenic expressions or gene ablations of core
fucosyl and other glycosyltransferases. The distribution of core
fucosylation in human tissues also forms the basis for extended studies
of potentially aberrant expression during malignant transformations and
other pathological processes.
FOOTNOTES
*
This work was supported by RO1-GM 32485 (to H. H. F.) and
RO1-CA 38701 (to A. V.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: The Burnham
Institute, 10901 North Torrey Pines Rd., La Jolla, CA 92037. Tel.: 619-455-6480; Fax: 619-646-3193; E-mail: hudson{at}ljcrf.edu.
1
The abbreviations used are: BSA, bovine serum
albumin; ELISA, enzyme-linked immunosorbent assay; TBS, Tris-buffered
saline; PBS, phosphate-buffered saline; HRP, horseradish peroxidase;
PLA2, phospholipase A2; pFg, porcine
fibrinogen; pTg, porcine thyroglobulin; EPO, erythropoietin; CHO,
Chinese hamster ovary; BCIP/NBT, 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium.
2
G. Srikrishna, L. Wang, and H. H. Freeze,
in preparation.
ACKNOWLEDGEMENTS
We thank Drs. Kevin Rice, Ole Hindsgaul, and
Pamela Stanley for their generous gifts of core-fucosylated
oligosaccharides, fucosylated-BSA conjugates, and CHO mutant cell
lysates, respectively. We also thank Khandrika Srikrishna for help with
the chemiluminescence assays and Susan Greaney for secretarial
help.
REFERENCES
-
Voynow, J. A., Kaiser, R. S., Scanlin, T. F., and Glick, M. C.
(1991)
J. Biol. Chem.
266,
21572-21577
[Abstract/Free Full Text]
-
Longmore, G. D., and Schachter, H.
(1982)
Carbohydr. Res.
100,
365-392
[CrossRef][Medline]
[Order article via Infotrieve]
-
Uozumi, N., Yanagidani, S., Miyoshi, E., Ihara, Y., Sakuma, T., Gao, C.-X., Teshima, T., Fujii, S., Shiba, T., and Tanuguchi, N.
(1996)
J. Biol. Chem.
271,
27810-27817
[Abstract/Free Full Text]
-
Bevilacqua, M. P., and Nelson, R. M.
(1993)
J. Clin. Invest.
91,
379-387
-
Kornfeld, S.
(1987)
FASEB J.
1,
462-468
[Abstract]
-
Varki, A.
(1997)
FASEB J.
11,
248-255
[Abstract]
-
Tang, J., Rutishauser, U., and Landmesser, L.
(1994)
Neuron
13,
405-414
[CrossRef][Medline]
[Order article via Infotrieve]
-
Baenziger, J. U., Kumar, S., Brodbeck, R. M., Smith, P. L., and Beranek, M. C.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
334-338
[Abstract/Free Full Text]
-
Kornfeld, K., Reitman, M. L., and Kornfeld, R.
(1981)
J. Biol. Chem.
256,
6633-6640
[Abstract/Free Full Text]
-
Bourne, Y., Mazurier, J., Legrand, D., Rouge, P., Montreuil, J., Spik, G., and Cambillau, C.
(1994)
Structure
2,
209-219
[Medline]
[Order article via Infotrieve]
-
Bourne, Y., Rouge, P., and Cambillau, C.
(1992)
J. Biol. Chem.
267,
197-203
[Abstract/Free Full Text]
-
Stubbs, H. J., Lih, J. J., Gustafson, T. L., and Rice, K. G.
(1996)
Biochemistry
35,
937-947
[CrossRef][Medline]
[Order article via Infotrieve]
-
Kojima, N., Tachida, Y., Yoshida, Y., and Tsuji, S.
(1996)
J. Biol. Chem.
271,
19457-19463
[Abstract/Free Full Text]
-
Suzuki, T., Seko, A., Kitajima, K., Inoue, Y., and Inoue, S.
(1994)
J. Biol. Chem.
269,
17611-17618
[Abstract/Free Full Text]
-
Dinter, A., and Berger, E. G.
(1995)
Adv. Exp. Med. Biol.
376,
53-82
[Medline]
[Order article via Infotrieve]
-
Aoyagi, Y., Isemura, M., Yosizawa, Z., Suzuki, Y., Sekine, C., Ono, T., and Ichida, F.
(1985)
Biochim. Biophys. Acta
830,
217-223
[CrossRef][Medline]
[Order article via Infotrieve]
-
Aoyagi, Y., Suzuki, Y., Isemura, M., Nomoto, M., Sekine, C., Igarashi, K., and Ichida, F.
(1988)
Cancer (Phila.)
61,
769-774
[CrossRef][Medline]
[Order article via Infotrieve]
-
Aoyagi, Y., Suzuki, Y., Igarashi, K., Yokota, T., Mori, S., Suda, T., Naitoh, A., Isemura, M., and Asakura, H.
(1993)
Cancer (Phila.)
72,
615-618
[CrossRef][Medline]
[Order article via Infotrieve]
-
Goodarzi, M. T., and Turner, G. A.
(1995)
Clin. Chim. Acta
236,
161-171
[CrossRef][Medline]
[Order article via Infotrieve]
-
Danguy, A., Akif, F., Pajak, B., and Gabius, H.-J.
(1994)
Histol. Histopathol.
9,
155-171
[Medline]
[Order article via Infotrieve]
-
Spicer, S. S., and Schulte, B. A.
(1992)
J. Histochem. Cytochem.
40,
1-38
[Medline]
[Order article via Infotrieve]
-
Walker, R. A.
(1989)
Pathol. Res. Pract.
185,
826-835
[Medline]
[Order article via Infotrieve]
-
Bell, C. M., and Skerrow, C. J.
(1984)
Br. J. Dermatol.
111,
517-526
[CrossRef][Medline]
[Order article via Infotrieve]
-
Nemanic, M. K., Whitehead, J. S., and Elias, P. M.
(1983)
J. Histochem. Cytochem.
31,
887-897
[Abstract]
-
Truong, L. D., Phung, V. T., Yoshikawa, Y., and Mattioli, C. A.
(1988)
Histochemistry
90,
51-60
[CrossRef][Medline]
[Order article via Infotrieve]
-
Capaldi, M. J., Dunn, M. J., Sewry, C. A., and Dubowitz, V.
(1985)
Histochem. J.
17,
81-92
[CrossRef][Medline]
[Order article via Infotrieve]
-
Nakagawa, F., Schulte, B. A., and Spicer, S. S.
(1986)
Cell Tissue Res.
245,
579-589
[Medline]
[Order article via Infotrieve]
-
Zachariah, B., Marikar, Y., and Basu, D.
(1991)
Indian J. Biochem. Biophys.
28,
412-417
[Medline]
[Order article via Infotrieve]
-
Damjanov, I.
(1987)
Lab. Invest.
57,
5-20
[Medline]
[Order article via Infotrieve]
-
Varki, A., and Marth, J.
(1995)
Semin. Dev. Biol.
6,
127-138
-
Lemieux, R. U., Baker, D. A., Weinstein, W. M., and Switzer, C. M.
(1981)
Biochemistry
20,
199-205
[CrossRef][Medline]
[Order article via Infotrieve]
-
Kamath, V. P., Diedrich, P., and Hindsgaul, O.
(1996)
Glycoconj. J.
13,
315-319
[CrossRef][Medline]
[Order article via Infotrieve]
-
Da Silva, M. L. C., Tamura, T., McBroom, T., and Rice, K. G.
(1994)
Arch. Biochem. Biophys.
312,
151-157
[CrossRef][Medline]
[Order article via Infotrieve]
-
Rice, K., Takahashi, N., Namiki, Y., Tran, A. D., Lisi, P. J., and Lee, Y. C.
(1992)
Anal. Biochem.
206,
278-287
[CrossRef][Medline]
[Order article via Infotrieve]
-
Crandall, I. E., and Newell, P. C.
(1989)
Development
107,
87-94
[Abstract]
-
Faye, L., Gomord, V., Fitchette-Laine, A. C., and Chrispeels, M. J.
(1993)
Anal. Biochem.
209,
104-108
[CrossRef][Medline]
[Order article via Infotrieve]
-
Haslam, S. M., Reason, A. J., Morris, H. R., and Dell, A.
(1994)
Glycobiology
4,
105-111
[Free Full Text]
-
Spik, G., Strecker, G., Fournet, B., Bouquelet, S., Montreuil, J., Dorland, L., van Halbeek, H., and Vliegenthart, J. F. G.
(1982)
Eur. J. Biochem.
121,
413-419
[Medline]
[Order article via Infotrieve]
-
Kurosaka, A., Yano, A., Itoh, N., Kuroda, Y., Nakagawa, T., and Kawasaki, T.
(1991)
J. Biol. Chem.
266,
4168-4172
[Abstract/Free Full Text]
-
Ishihara, H., Takahashi, N., Oguri, S., and Tejima, S.
(1979)
J. Biol. Chem.
254,
10715-10719
[Abstract/Free Full Text]
-
Green, E. D., Adelt, G., Baenziger, J. U., Wilson, S., and Van Halbeek, H.
(1988)
J. Biol. Chem.
263,
18253-18268
[Abstract/Free Full Text]
-
Tai, T., Yamashita, K., Ogata-Arakawa, M., Koide, N., Muramatsu, T., Iwashita, S., Inoue, Y., and Kobata, A.
(1975)
J. Biol. Chem.
250,
8569-8575
[Abstract/Free Full Text]
-
Yoshima, H., Matsumoto, A., Mizuochi, T., Kawasaki, T., and Kobata, A.
(1981)
J. Biol. Chem.
256,
8476-8484
[Abstract/Free Full Text]
-
de Waard, P., Koorevaar, A., Kamerling, J. P., and Vliegenthart, J. F. G.
(1991)
J. Biol. Chem.
266,
4237-4243
[Abstract/Free Full Text]
-
Cummings, R. D.
(1994)
Methods Enzymol.
230,
66-86
[Medline]
[Order article via Infotrieve]
-
Campbell, C., and Stanley, P.
(1984)
J. Biol. Chem.
259,
13370-13378
[Abstract/Free Full Text]
-
Raju, T. S., and Stanley, P.
(1996)
J. Biol. Chem.
271,
7484-7493
[Abstract/Free Full Text]
-
Raju, T. S., Ray, M. K., and Stanley, P.
(1995)
J. Biol. Chem.
270,
30294-30302
[Abstract/Free Full Text]
-
Ripka, J., Adamany, A., and Stanley, P.
(1986)
Arch. Biochem. Biophys.
249,
533-545
[CrossRef][Medline]
[Order article via Infotrieve]
-
Pereira, M. E., Kisailus, E. C., Gruczo, F., and Kabat, E. A.
(1978)
Arch. Biochem. Biophys.
185,
108-115
[CrossRef][Medline]
[Order article via Infotrieve]
-
Walker, R. A.
(1985)
J. Pathol.
146,
123-127
[CrossRef][Medline]
[Order article via Infotrieve]
-
West, C. M., Erdos, G. W., and Davis, R.
(1986)
Mol. Cell. Biochem.
72,
121-140
[CrossRef][Medline]
[Order article via Infotrieve]
-
Freeze, H. H.
(1992)
in
Cell Surface Carbohydrates and Cell Development (Fukuda, M., ed), pp. 285-317, CRC Press, Inc., Boca Raton, FL
-
Ivatt, R. J., Das, O. P., Henderson, E. J., and Robbins, P. W.
(1984)
Cell
38,
561-567
[CrossRef][Medline]
[Order article via Infotrieve]
-
Sharkey, D. J., and Kornfeld, R.
(1991)
J. Biol. Chem.
266,
18485-18487
[Abstract/Free Full Text]
-
Kornfeld, R., and Kornfeld, S.
(1985)
Annu. Rev. Biochem.
54,
631-664
[CrossRef][Medline]
[Order article via Infotrieve]
-
Lin, A. I., Philipsberg, G. A., and Haltiwanger, R. S.
(1994)
Glycobiology
4,
895-901
[Abstract/Free Full Text]
-
Endo, T., Fujiwara, T., Ikehara, Y., and Kobata, A.
(1996)
Eur. J. Biochem.
236,
579-590
[Medline]
[Order article via Infotrieve]
-
Katz, F., Moats, W., and Jan, Y. N.
(1988)
EMBO J.
7,
3471-3477
[Medline]
[Order article via Infotrieve]
-
Sawutz, D. G., Lanier, S. M., Warren, C. D., and Graham, R. M.
(1987)
Mol. Pharmacol.
32,
565-571
[Abstract]
-
George, S. T., Ruoho, A. E., and Malbon, C. C.
(1986)
J. Biol. Chem.
261,
16559-16564
[Abstract/Free Full Text]
-
Shirakawa, O., Kuno, T., and Tanaka, C.
(1983)
Biochem. Biophys. Res. Commun.
115,
814-819
[CrossRef][Medline]
[Order article via Infotrieve]
-
Ishii, S., and Volpe, J. J.
(1992)
Dev. Neurosci.
14,
221-229
[Medline]
[Order article via Infotrieve]
-
Bhat, N. R., and Waechter, C. J.
(1988)
J. Neurochem.
50,
375-381
[CrossRef][Medline]
[Order article via Infotrieve]
-
Regan, C. M.
(1991)
Int. J. Biochem.
23,
513-523
[CrossRef][Medline]
[Order article via Infotrieve]
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. C. Adam, S. T. Holgate, and P. M. Lackie
Epithelial repair is inhibited by an {alpha}1,6-fucose binding lectin
Am J Physiol Lung Cell Mol Physiol,
February 1, 2007;
292(2):
L462 - L468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Noda, E. Miyoshi, J. Gu, C.-X. Gao, S. Nakahara, T. Kitada, K. Honke, K. Suzuki, H. Yoshihara, K. Yoshikawa, et al.
Relationship between Elevated FX Expression and Increased Production of GDP-L-Fucose, a Common Donor Substrate for Fucosylation in Human Hepatocellular Carcinoma and Hepatoma Cell Lines
Cancer Res.,
October 1, 2003;
63(19):
6282 - 6289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Wang, W. Li, Y. Ikeda, J.-I. Miyagawa, M. Taniguchi, E. Miyoshi, Y. Sheng, A. Ekuni, J. H. Ko, Y. Yamamoto, et al.
Ectopic expression of {{alpha}}1,6 fucosyltransferase in mice causes steatosis in the liver and kidney accompanied by a modification of lysosomal acid lipase
Glycobiology,
February 1, 2001;
11(2):
165 - 174.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Srikrishna, D. K. Toomre, A. Manzi, K. Panneerselvam, H. H. Freeze, A. Varki, and N. M. Varki
A Novel Anionic Modification of N-Glycans on Mammalian Endothelial Cells Is Recognized by Activated Neutrophils and Modulates Acute Inflammatory Responses
J. Immunol.,
January 1, 2001;
166(1):
624 - 632.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Marquardt, K. Luhn, G. Srikrishna, H. H. Freeze, E. Harms, and D. Vestweber
Correction of Leukocyte Adhesion Deficiency Type II With Oral Fucose
Blood,
December 15, 1999;
94(12):
3976 - 3985.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A Journet, A Chapel, S Jehan, C Adessi, H Freeze, G Klein, and J Garin
Characterization of Dictyostelium discoideum cathepsin D
J. Cell Sci.,
January 11, 1999;
112(21):
3833 - 3843.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. S. Raju and P. Stanley
Gain-of-function Chinese Hamster Ovary Mutants LEC18 and LEC14 Each Express a Novel N-Acetylglucosaminyltransferase Activity
J. Biol. Chem.,
June 5, 1998;
273(23):
14090 - 14098.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1997 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|